# Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis

> **NCT01385826** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 34 (actual)

## Conditions studied

- Uveitis
- Juvenile Arthritis

## Interventions

- **DRUG:** Anti-tumor necrosis factor alpha monoclonal antibody
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01385826
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-29
- **Primary completion:** 2014-11-04
- **Final completion:** 2015-08-27
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01385826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01385826, "Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT01385826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*